Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $1.61M fell 26.0% year over year, ahead of the -44.2% change in trailing-twelve-month research & development. Sequentially, it fell 28.6% from the prior quarter. Over 3 fiscal years it compounded at -9.8% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -26.0% holds above the trailing-twelve-month pace of -44.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.61M-28.6% QoQ
Last fiscal yearDec 2025
$9.12M-54.4% YoY
LTMMar 2026
$8.57M-44.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.0%——
1 year-54.4%——
3-year CAGR-9.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
9.12M USD
Year-over-year change
-54.4%
4-year CAGR
+10.7%

Research & Development vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.2% is the 8th highest of 10, against a peer median of -3.9%.
  • Over three fiscal years its annual growth of -9.8% compares with a peer median of +7.7%.
UNCY Competitors
Research & Development for UNCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$200.25M USD+133.0%+35.5%78.3%
IMUXImmunic, Inc.LTM Mar 2026$86.08M USD+3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M USD+8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M USD-11.8%+35.8%—
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M USD-55.0%-0.4%—
CBUSCibus, Inc.LTM Mar 2026$41.12M USD-18.1%+56.4%959.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$37.7M USD-3.9%—958.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M USD-48.6%-81.3%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$8.57M USD-44.2%-9.8%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$4.56M CAD+1.7%-13.6%24.8%
Peer median (excluding UNCY) —-3.9%+7.7%518.3%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0951K675K00
Cost of Revenue0000572K
Gross Profit0951K675K0(572K)
Gross Margin—100.0%100.0%——
Research & Development6.08M12.44M12.9M20.01M9.12M
Selling, General & Admin2.9M6.57M8.55M12.1M20.4M
Operating Expenses8.98M19M21.45M32.12M28.95M
Depreciation & Amortization13K161K284K428K572K
EBITDA(9.38M)(17.89M)(30.18M)(36.23M)(25.91M)
EBITDA Margin—-1881.3%-4470.8%——
Operating Income(8.98M)(18.05M)(20.77M)(32.12M)(29.52M)
Operating Margin—-1898.2%-3077.6%——
Interest Income00615K1.26M1.01M
Interest Expense628K6K82K71K71K
Other Income / Expenses(1.04M)(6K)(9.77M)(4.61M)2.96M
Income Before Tax(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Pre-Tax Margin—-1898.8%-4525.0%——
Income Tax Expense00000
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Net Margin—-1898.8%-4525.0%——
EPS (Basic)(8.60)(1.20)(1.28)(5.60)(1.67)
EPS (Diluted)(8.60)(1.20)(1.28)(5.60)(1.67)
Weighted Avg Shares1.17M1.51M2.45M6.7M158.87M
Weighted Avg Shares (Diluted)1.17M1.51M2.45M6.7M158.87M

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.